Salvat, WraSer Pharmaceuticals LLC sales and marketing update

Salvat granted WraSer exclusive, U.S. commercialization rights to Cetraxal 0.2% ciprofloxacin solution for 10 years. FDA approved Cetraxal in May to treat acute otitis externa (swimmer's ear). Cetraxa...